Astellas inks agreement with Dyno Therapeutics for access to its CapsidMap platform for novel AAV vectors. Taiho takes option to Arcus TIGIT-targeted antibody candidates.

Despite a pending domestic approval for BioNTech/Fosun's COVID-19 vaccine, China’s apparent belief in another, domestically developed, mRNA vaccine sees a large group of investors pour hundreds of millions into a little-known private bioventure founded by an ex-Moderna scientist and poised to take on the US biotech.

Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.

Amid a sweeping National Security Law passage, many biotech and healthcare firms from China opt for a Hong Kong initial public offering in the meanwhile appetite for a US listing wanes.